At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Hydroxychloroquine Sulfate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating Hydroxychloroquine Sulfate and LY3214996 for Pancreatic Cancer and Advanced Cancer. Completed, enrolled 52 participants across 4 sites.
Detailed Summary
This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer, Advanced Cancer
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartMay 2020
Primary CompletionAug 2023
Study CompletionFeb 2024
TodayJul 2026
First PostedMay 13, 2020
Enrollment StartMay 27, 2020
Primary CompletionAug 9, 2023
Study CompletionFeb 5, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.1 years ago
Interventions
Hydroxychloroquine Sulfatedrug
HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle
LY3214996drug
LY3214996-daily oral dosage per protocol per 28 day cycle